A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2018
Price : $35 *
At a glance
- Drugs TF 6450 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Theravance
- 25 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 10 Jan 2014 New trial record